Tune Therapeutics Secures $175M to Advance Epigenetic Editing into Clinical Trials
Funding:
Tune Therapeutics has raised $175 million to bring epigenetic editing to the clinic, bucking the downturn in gene editing investments5.
Technology:
Tune Therapeutics uses its TEMPO platform, which employs CRISPR as an epigenome-editing tool, to reprogram the epigenome in a site-specific manner without creating double-stranded breaks3.
Applications:
The technology has potential applications in treating complex diseases caused by changes in more than one gene, including cardiovascular conditions, cancer, and neurodegenerative disorders3.
Lead Candidate:
Tune Therapeutics' lead candidate, TUNE-401, aims to epigenetically silence the hepatitis B virus (HBV), offering hope for a functional cure3.
Clinical Potential:
Epigenetic editing combines the power of multiplexing with precise control of expression, expanding the reach of gene therapies and enhancing cell therapies1.
Market Context:
The funding comes at a time when gene editing investments have seen a downturn, highlighting the growing interest in epigenetic editing as a safer and more versatile alternative5.
Sources:
1. https://www.drugtargetreview.com/article/110654/epigenetic-editing-the-next-generation-of-genetic-medicine/
3. https://crisprmedicinenews.com/news/tune-therapeutics-can-epigenome-editing-cure-hepatitis-b/